September 22, 2021

W. L. Gore & Associates améliore le portefeuille d’endoprothèses GORE® VIABAHN® avec la pose d’un profil plus bas

Les améliorations apportées aux dispositifs de grand diamètre comprennent l’accessibilité par des gaines plus petites tout en permettant une meilleure visualisation grâce à l’ajout de marqueurs radio-opaques

25 ans d’innovation continue

PUTZBRUNN, Allemagne, 22 septembre 2021 /PRNewswire/ — Dans le cadre de ses efforts pour améliorer continuellement les solutions médicales pour les patients souffrant de maladies vasculaires complexes, W. L. Gore & Associates, Inc. (Gore) a annoncé le lancement dans la région EMEA de l’endoprothèse GORE^® VIABAHN^® à profil plus bas et à grand diamètre avec surface bioactive PROPATEN. Les améliorations apportées à ce dispositif s’appuient sur une endoprothèse leader sur le marché, qui est devenue un outil important pour le traitement des maladies vasculaires complexes. La conception innovante du dispositif VIABAHN^® réduit le profil de pose des grandes endoprothèses de 9 à 13 mm de diamètre jusqu’à 3 CH, ce qui permet de les poser dans des gaines plus petites. Des gaines d’introduction plus petites ont permis de réduire le risque de complications liées à l’accès vasculaire chez certaines populations de patients.¹ En outre, de nouveaux marqueurs radio-opaques, désormais présents sur les configurations de dispositifs de plus grand diamètre, améliorent la visualisation sous fluoroscopie, facilitant le positionnement et la pose du dispositif, ainsi qu’un placement précis et prévisible. « Outre les marqueurs radio-opaques qui facilitent le positionnement et le déploiement, le nouveau profil plus bas permet d’utiliser une gaine plus petite, ce qui réduit potentiellement le risque de dommages au niveau du site d’accès », a déclaré Manuel Alonso, docteur en médecine, chirurgien vasculaire, Oviedo, Espagne. « Associée à la traçabilité et à la flexibilité, cette nouvelle offre de profil plus bas deviendra très utile dans ma pratique pour traiter les patients complexes dans tous les états pathologiques. »

GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface

« L’histoire de l’endoprothèse GORE^® VIABAHN^® est l’histoire d’une collaboration entre médecins pour quatre indications centrées sur le patient et d’une performance prouvée à maintes reprises », a déclaré Benjamin Beckstead, responsable de la catégorie vasculaire chez Gore.

Depuis son lancement dans l’UE en 1996, le dispositif a évolué grâce à de nombreuses améliorations et a pris en charge des centaines de milliers de patients dans le monde entier. Actuellement, le dispositif VIABAHN^® est utilisé dans de nombreuses indications cliniques telles que les lésions de l’artère fémorale superficielle (AFS), les lésions iliaques, la resténose intra-stent des lésions de l’AFS et les lésions du circuit d’accès artério-veineux (AV).*

Pour plus d’informations, rendez-vous sur le site https://www.goremedical.com/eu/products/viabahn

* Pour obtenir des indications complètes et d’autres informations importantes sur la sécurité des produits commerciaux Gore mentionnés dans le présent document, reportez-vous aux instructions d’utilisation.

1. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. JACC : Cardiovascular Interventions 2008;1(3):317-326.

Gore conçoit des dispositifs médicaux qui traitent toute une série de maladies cardiovasculaires et d’autres problèmes de santé. Avec plus de 50 millions de dispositifs médicaux implantés pendant plus de 45 ans, Gore s’appuie sur sa réputation pour améliorer le pronostic des patients à travers la recherche, la formation et la démarche qualité. L’efficacité des produits, la facilité d’utilisation et la qualité du service permettent aux médecins, aux hôpitaux et aux assureurs de réaliser des économies significatives. Gore est au service des cliniciens et grâce à cette collaboration, nous améliorons des vies.

À propos de Gore

W. L. Gore & Associates est une entreprise internationale spécialisée dans la science des matériaux et dont l’objectif est l’amélioration du secteur et des conditions de vie. Depuis 1958, Gore répond à des défis techniques complexes dans des environnements exigeants – de l’espace aux plus hauts sommets du monde en passant par le fonctionnement interne du corps humain. Avec plus de 11 000 associés et une forte culture axée sur le travail en équipe, Gore génère un chiffre d’affaires annuel de $3,8 milliards de dollars.

gore.com

Les produits énumérés peuvent ne pas être disponibles sur tous les marchés.

GORE, together, improving life, PROPATEN et HELEX, et les modèles sont des marques déposées de W. L. Gore & Associates.

Photo – https://mma.prnewswire.com/media/1628622/GORE_VSX_LDPro_final_highres.jpg

Logo – https://mma.prnewswire.com/media/340166/W_L_Gore_and_Associates_Logo.jpg

September 22, 2021

W. L. Gore & Associates Enhances GORE® VIABAHN® Endoprosthesis Portfolio With Lower Profile Delivery

Improvements to large diameter devices include accessibility through smaller sheaths while providing enhanced visualization by adding radiopaque markers

25 years of continued innovation

PUTZBRUNN, Germany, Sept. 22, 2021 /PRNewswire/ — As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced the EMEA launch of the lower profile, large diameter GORE^® VIABAHN^® Endoprosthesis with PROPATEN Bioactive Surface. The device enhancements build on a market-leading stent graft device, which has become an important tool for treating complex vascular disease. The innovative VIABAHN^® Device design reduces the delivery profile for larger 9–13 mm diameter stent grafts by up to 3 Fr, enabling delivery through smaller sheaths. Smaller introducer sheaths have resulted in a lower risk of vascular access complications in select patient populations.¹ Additionally, new radiopaque markers, now also on the larger diameter device configurations, enhance visualization under fluoroscopy, facilitating positioning and device delivery, as well as precise and predictable placement. “In addition to the radiopaque markers that facilitate positioning and deployment, the new lower profile enables use of a smaller sheath, potentially reducing the risk of damage at the access site,” said Manuel Alonso, M.D., Vascular Surgeon, Oviedo, Spain. “Combined with the trackability and flexibility this new lower profile offering will become very instrumental for treating complex patients across disease states in my practice.”

“The story of the GORE^® VIABAHN^® Endoprosthesis is a story of physician collaboration across four patient-centric indications and of proving performance over and over,” said Benjamin Beckstead, Gore Vascular Category Leader.

Since its EU launch in 1996, the device has evolved with numerous enhancements and supported hundreds of thousands of patients worldwide. Currently, the VIABAHN^® Device is used in various clinical indications such as in superficial femoral artery (SFA) lesions, iliac lesions, in-stent restenosis of SFA lesions and AV Access circuit lesions.*

For more information, visit https://www.goremedical.com/eu/products/viabahn

* For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).

1. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. JACC: Cardiovascular Interventions 2008;1(3):317-326.

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion.

gore.com

Products listed may not be available in all markets.

GORE, Together, improving life, PROPATEN, VIABAHN and designs are trademarks of W. L. Gore & Associates.

Photo – https://mma.prnewswire.com/media/1628622/GORE_VSX_LDPro_final_highres.jpg

Logo – https://mma.prnewswire.com/media/340166/W_L_Gore_and_Associates_Logo.jpg

September 22, 2021

Arctic Sea Ice Shrank Less in 2021, Scientists Say

Scientists with the National Snow and Ice Data Center (NSIDC) in the U.S. state of Colorado said Wednesday that, as summer was ending in the Northern Hemisphere, Arctic sea ice had shrunk less in 2021 than in other recent years.

Supported by NASA and other federal agencies, the NSIDC is part of the Cooperative Institute for Research in Environmental Sciences at the University of Colorado in Boulder. It is among the research organizations that monitor the ebb and flow of the Arctic ice pack. Scientists with the center determined the ice pack reached its minimum extent for the year on September 16.

Sea ice extent is defined as the total area in which ice concentration is at least 15%

This year, satellite observations determined Arctic ice covered a minimum of 1.82 million square kilometers, which NSIDC scientists said was the highest minimum coverage since 2014, and the 12th lowest in 43 years of satellite records.

In a statement, NSIDC Director Mark Serreze said, “We had a reprieve this year — a cool and stormy summer with less ice melt. But the amount of old, thick sea ice is as low as it has ever been in our satellite record.”

The NSIDC said the last 15 years have produced the lowest 15 sea ice extents in the satellite record. The amount of old, multiyear ice — that is, ice that has remained frozen through at least one summer melt season — is at one of the lowest levels in the ice age record, which began in 1984.

The center cautioned the Arctic Sea ice extent figures were preliminary, as continued melting could still push the ice minimum extent lower before the early winter freeze begins. NSIDC will issue a formal announcement at the beginning of October with full analysis of the possible causes behind this year’s ice conditions.

Source: Voice Of America

September 22, 2021

WHO: Reducing Air Pollution Could Save Millions of Lives

The World Health Organization is issuing new guidelines on improving global air quality, which it says could save many of the seven million lives that are lost each year to pollution.

WHO Director-General Tedros Adhanom Ghebreyesus says inhaling dirty air increases the risk of pneumonia, asthma, and chronic obstructive pulmonary diseases, as well as noncommunicable ailments including heart disease, stroke and cancers.

“Air pollution is a health threat in all countries but especially for vulnerable groups in low- and middle-income countries with poor air quality due to urbanization and rapid economic development and air pollution in the home caused by cooking, heating and lighting,” he said.

Since the WHO’s last global update in 2005, a new body of evidence has emerged showing that humans suffer damage to their health at lower concentrations of air pollution than previously believed.

Consequently, the WHO recommends lower air quality levels for five key pollutants, including nitrogen dioxide, sulfur dioxide, and carbon monoxide.

Maria Neira, director of the WHO’s department of environment, climate change and health, says a changeover to cleaner energy will improve people’s health and mitigate global warming.

“Moving to renewable and clean sources of energy because [of] this will have a very positive impact on reducing the greenhouse gases emission and tackling the causes of climate change and reducing air pollution,” she said. “Both are critical pillars of our health.”

Besides improving health and saving lives, reducing air pollution could also have enormous economic benefits.

The World Bank estimates the global cost associated with health damage from ambient air pollution stands at $5.7 trillion a year.

Source: Voice Of America